Company intelligence / Profile preview

Greenman Bio-Pharmaceuticals

Qingdao, Shandong, China

Ownership: Private
Employees: ~300
Development stage: Other

Overview

Greenman Bio-Pharmaceuticals is an established biochemical pharmaceutical company specializing in the research, development, and high-purity manufacture of biochemical raw materials (APIs) and finished dosage forms. The company is particularly recognized for its expertise in glycosaminoglycans, producing high-quality heparin sodium and chondroitin sulfate for global markets. Their products are primarily used in the treatment of cardiovascular diseases and joint-related conditions, with several programs having achieved commercial status and international regulatory certification.

Therapeutic areas: HematologyCardiovascularRheumatology
Modalities: BiologicSmall moleculeProtein
Industry: Biotech

Beyond the preview

Go deeper on Greenman Bio-Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Greenman Bio-Pharmaceuticals.

Explore the full profile